GE Healthcare

Life Sciences

Cell technologies.
Your vision. Our expertise.
Imagine the possibilities...
Uncover the potential that
lies within the cell.
“GE Healthcare’s cell technology strategy is aimed at harnessing the
vast potential in stem cell applications as part of an overall cellular
science portfolio.
To this end, we are determined to lead the way by investing in a stronghold
of expertise within the cell dimension. Today we offer customized solutions
for cell-based assays, together with a sophisticated platform for high-content
analysis. Plus, we are developing cellular assay products derived from human
embryonic stem cells for use in drug discovery, development, and toxicity
screening. We are also continuously expanding our portfolio of innovative
solutions that can be utilized to grow the future of cell therapy.
I am also proud to have Dr. Stephen Minger, who directed the first group that
banked an embryonic stem cell in the UK cell bank, as our head of research
and development for GE Healthcare’s products for cell technology.
I am confident that, with the extensive expertise of our team, we will keep
pushing the frontiers of science and technology forward to enable scientists
and researchers to maximize the potential that lies within the cell.”

Dr. Konstantin Fiedler

General Manager cell technologies
GE Healthcare

3
You have the ideas. We have the technologies
to help you bring them to life.
“I believe there is one company capable of making a sustainable difference in the world of stem cell
biology. That company is GE Healthcare, with its immense expertise, global resources, sophisticated
research centers, and commitment to technological innovation. Today GE Healthcare not only has
the capacity to develop cellular assay products derived from human stem cells, but also offers a
sophisticated cell imaging platform and systems to grow the future of cell therapy. I believe we are
truly at the cusp of realizing the defining power of human stem cells on the future of healthcare.”
Dr. Stephen Minger

Stem cell biology opens exciting opportunities for breakthrough to see, to fathom, and to achieve. With GE Healthcare by your side,
scientific and medical discovery, research, and application. With the you can push the frontiers of scientific discovery forward so that
breadth of GE Healthcare’s knowledge and experience in cell biology today’s platforms help achieve better drug discovery and therapy
at your disposal, you can rely on our profound expertise to help you for all our tomorrows.

IN Cell Analyzer
 Process Opt
imizatio
n • S
cale-u
p • QC
Basic Research Translational Rese /Q A
arch C • c
GMP
linical
Trials
Cell
The
rap
y C
ord
Blo
o dB
an
k in
WAVE Bioreactor™ g
Res-Q™ 60 BMC Celution 800/CRS*
®
2/10 and 20/50 systems
AXP™ AutoXpress™ system
Density Gradient Media

Cell Therapy Expansion

Separation
Scale-up
Development and production of cells Processing Differentiation
for therapeutic use. Characterization
GE Healthcare provides tools to Assay Development Engineering

Cell Expertise
prepare and handle the cells (enrich,
expand, process).

Stem Cells Purification

Industrial Scale Culture
Drug Discovery Image Analysis Imaging
Understanding of disease mechanisms and
testing of drug candidates. Bioinformatics

GE Healthcare uses its cell biology expertise to

provide cellular analysis tools and cells to test
drug candidates.

Stem cell
g
derived models stin
Te
ls ity
al Tria To
xic
ic •
Clin
Cell Factory
ion
zat
i
ry tim
ove Op
WAVE Bioreactor ™
isc e ad
D • L
2/10 and 20/50 systems Drug ening
cre
arch • S
Rese tion
Basic et Valida
Targ Available in Europe only
*
•
ation
Id entific 5
Target
Your goals. Our customized services.
Expand your capacity through Cell Factory.
“We have been using batches of frozen cells from GE for several years now. The batches are always
delivered on time, and consistently perform as well as we expect in the assays in which we use them.
Having a reliable outsourcing option such as that provided by GE, in addition to our own in house
capabilities, gives us the flexibility we need to deal with our ever changing cell requirements.”
Peter Stacey, Ph.D., Principal Scientist, Research Enabling Group, Pfizer, UK

Welcome to Cell Factory: a range of services to facilitate research screening and technological expertise in the preparation of bulk
using cell-based assays particularly for high-throughput and high- quantities of cryopreserved cells. Moreover, the application of Design for
content screening. Cell Factory is designed to meet the particular Six Sigma to all core processes ensures consistent quality and reliability.
needs of large-scale cell production and efficient assay development.
Our high levels of service and operational excellence ensure
Cell Factory is built upon GE Healthcare’s leading position in high-content consistently high user satisfaction.

SERVICE DESCRIPTION
Assay design Design and building of assays using commercial or customer reagents
Assay optimization Formatting of assays to customer criteria and metrics
Transient cell engineering Large-scale sensor or target expression with validation to customer specification
Stable cell engineering Sensor or target expression, selection of clones, and validation
Bulk cell culture Large-scale (> 109) cell expansion
Plate preparation Cells predispensed onto plates ready for HTS/HCA
Imaging and analysis Image acquisition, analysis, and data mining to customer requirements

6
Relevant. Reliable. Confident.
A new era in safety screening with
advanced cell models.
“Now we can provide cells of reproducible nature and consistent subtype, and we know this because
we are growing them day in, and day out.”
Dr. Stephen Minger

Building on our Cell Factory capability for bulk cell manufacturing, the pharmacological characteristics of a drug candidate than the
our key focus is the commercial production of cellular assay products animal cell models or in vitro tests currently used.
derived from human embryonic stem cells (hES cells).
Cardiotoxicity and hepatotoxicity are the most common causes
Earlier detection, or prediction, of toxicity problems could significantly of drug safety liabilities. Thus, our initial focus is the derivation
reduce overall drug development costs. Cells derived from hES cells of functional cardiomyocytes and hepatocytes, to provide a
have similar attributes to their counterparts in the human body, reliable, industrial-scale supply of cells for safety screening of
making them much more relevant for the accurate prediction of drug candidates.

7
Visualize. Analyze. Realize. The power to
probe deeper with IN Cell Analyzer.
“High content imaging technologies have become indispensable tools in the advancement of our
understanding of how the human body works at the cellular level. These new research platforms
provide the capacity to generate hundreds of times more scientifically valuable information than the
conventional analysis technologies that are currently in use today.”
Anthony Davies, Director of High Content Research Facility, Department of Clinical Medicine, Trinity College Dublin

With the ability to see deeper comes the capacity to analyze, and molecular function in normal and disease states; to study cell
ultimately to realize new insights . When yesterday you had sight, today behavior in depth; and to even screen for new targets and illuminate
you have insight with IN Cell Analyzer – a system that automatically mechanisms of action or potential toxic profiles of drug candidates.
extracts and analyzes quantitative data from cellular images.
IN Cell Analyzer supports an amazing depth and breadth of
The remarkable monitoring and analysis capabilities of IN Cell investigation, while it ensures highly relevant and precise data. This
Analyzer allow you to comprehend functional biology at the cellular means that you can be much more confident of your results and
level: to probe complex signaling mechanisms and elucidate save valuable time and resources.

8
IN Cell Analyzer 2000
Cell analysis just got easier
IN Cell Analyzer 2000 is an automated microscope that images and analyzes both
fluorescently stained and unlabeled cells in a high-throughput format. Data is captured in
both a spatial and temporal context.
• Live or fixed cells, tissues, and organisms.
• Remarkable imaging flexibility enabled by a wide range of objectives (2 to 100×) and an
extraordinary 4 Mp imaging camera to allow subcellular resolution or whole well imaging.
• Microtiter plates or slides.
• Compatible with robotics for screening applications.

IN Cell Investigator Analysis Software

Intuitive. Flexible. Powerful
IN Cell Analyzer is seamlessly supported with a comprehensive suite of analysis tools to
maximize data extraction and understanding. IN Cell Investigator is designed by biologists
to be both user-friendly and powerful enough to deal with the most challenging biologies.
• Ability to measure and analyze over 70 morphological and intensity
parameters automatically.
• Conduct automated analyses and data visualization.
• Reanalyze stored data as hypotheses evolve.

IN Cell Miner
Locate. Collaborate. Communicate
Data is your asset. IN Cell Miner is the comprehensive data management system of
the IN Cell Analyzer product suite. IN Cell Miner is based on an industry accepted data
management system, EMC Documentum.
• A robust and scalable solution that allows you to visually organize and retrieve your
project data easily.
• Compare existing data with past and future data or reanalyze data in the light of
new information.

9
Your vision. Our solutions. The confidence
to achieve clinical success.
“We are re-educating and re-targeting the immune system with clinical trials to target cancer and HIV.
With the help of the WAVE Bioreactor, we are able to easily produce engineered T cells at doses well
above 1 × 1010. The Wave perfusion culture system allows high density culture of T lymphocytes and
reduction of residuals, such as vectors used for gene transfer.”
Bruce L. Levine, Ph.D., Associate Professor at University of Pennsylvania
Director, Clinical Cell and Vaccine Production Facility at University of Pennsylvania

GE Healthcare has a steadily growing range of innovative solutions

that you can utilize to grow the future of cell therapy. These include
systems to reliably process cord blood and bone marrow, enrich
adipose derived stem cells, enrich mononuclear cells through density
gradient media, and expand cells in suspension.

Manual Cell Separation

Ficoll-Paque™ PREMIUM
Ficoll-Paque PREMIUM products are sterile, ready–to-use density gradient media used to produce different
density preparations of mononuclear cells from peripheral blood, bone marrow, and umbilical cord blood by
density gradient centrifugation. All Ficoll-Paque PREMIUM products are manufactured according to GMP and
ISO 13485:2003 standards and the recommendations of the United States Pharmacopeia.

Automated Cell Expansion

WAVE Bioreactor 2/10 and 20/50 systems*

WAVE Bioreactor systems provide a robust process for manufacturing human suspension cells with
perfusion in a single disposable Cellbag™ bioreactor. The expanded cells remain biologically functional and
can be re-activated to produce high amounts of cytokines.

*
WAVE Bioreactor system for clinical applications in cell therapy is for research use only and for use under IND or IDE cleared by FDA in US.

10
Automated Cell Processing Systems
Celution 800/CRS
Celution 800/CRS System gives you real-time access to adipose-derived stem and regenerative cells (ADRCs).
The system facilitates automated extraction, washing, and concentration of ADRCs. It is also capable of
effectively preparing ADRC-enhanced fat grafts as well as collecting tissue and treating the tissue using the
same procedures.

AXP AutoXpress system

AXP AutoXpress system is an automated, functionally closed, and sterile system for volume reduction of cord
blood components. This system delivers consistently high recoveries of mononucleated cells (MNCs) from
cord blood with or without the addition of HES. The AXP AutoXpress system is also capable of simultaneous
processing of multiple cord blood units.

Res-Q 60 BMC
Res-Q 60 BMC (Bone Marrow Concentration) is a point-of-care system designed to provide high quality
cell concentrates of bone marrow derived stem cells easily, consistently, and reliably from bone
marrow aspirates.

StemSource 900/MB
StemSource 900/MB Tissue Processing System is a sterile, closed system that automatically processes
tissue to yield large numbers of diverse primary regenerative cell types for research use. High stem and
regenerative cell yield delivers on average 4.6 × 107 nucleated cells from 100 g of tissue.

11
GE, Imagination at work, and GE monogram are GE Healthcare UK Limited
trademarks of General Electric Company. Amersham Place,
Little Chalfont
Ficoll-Paque, Cellbag, and WAVE Bioreactor are Buckinghamshire, HP7 9NA
trademarks of GE Healthcare companies. UK

All third party trademarks are the property of their GE Healthcare Europe, GmbH
respective owners. Munzinger Strasse 5
D-79111 Freiburg
The StemSource 900/MB Tissue Processing /System for Germany
research applications is distributed by GE Healthcare
in the following countries: UK, Norway, Austria, France, GE Healthcare Bio-Sciences
Denmark, Switzerland, Germany, Sweden, Belgium, Corporation
Netherlands, Luxemburg, North America, Canada, and 800 Centennial Avenue,
Mexico. For countries not appearing on the list, please P.O. Box 1327
contact Cytori Therapeutics directly (www.Cytoritx.com). Piscataway, NJ 08855-1327
USA
The Celution 800/CRS System is distributed by GE
Healthcare in the following countries: UK, Norway, Austria, GE Healthcare Japan
France, Denmark, Switzerland, Germany, and Sweden. For Corporation
countries not appearing on the list, please contact Cytori Sanken Bldg., 3-25-1,
Therapeutics directly (www.Cytoritx.com). Hyakunincho
Shinjuku-ku, Tokyo 169-0073
©2010 General Electric Company - All rights reserved. Japan
First published October 2010.

For local office contact information, visit:

www.gelifesciences.com/contact

GE Healthcare Bio-Sciences AB
Björkgatan 30
751 84 Uppsala
Sweden

28-9800-88 AB 10/2010